Ultra-LEAF™ Purified anti-mouse IL-4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Partially purified native mouse IL-4

Formulation

0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.

Endotoxin Level

Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.

Preparation

The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Concentration

The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.

Application

ELISA Capture - Quality tested
CyTOF® - Verified
ELISPOT Capture, Neut, ICC, IP, IHC - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISPOT applications, a concentration range of 2-6 μg/ml is recommended. For ELISA capture applications, a concentration range of 0.5-2.0 μg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-4 recombinant protein ranging from 250 to 2 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA^1,2,10,13 or ELISPOT⁵ Capture: The purified 11B11 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD6-24G2 antibody (Cat. No. 504202) as the detecting antibody and recombinant mouse IL-4 (Cat. No. 575609) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture.
Neutralization^1-2,9,12: The 11B11 antibody can neutralize the bioactivity of natural or recombinant IL-4. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IL-4 bioactivity in vivo and in vitro (Cat. No. 504108).
Additional reported applications (for the relevant formats) include: immunoprecipitation¹⁶, immunohistochemical staining of formalin-fixed paraffin-embedded tissue sections⁸ and paraformaldehyde-fixed, saponin-treated frozen tissue sections^6,7, and immunocytochemistry⁴.
Note: For testing mouse IL-4 in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 431101 to 431106) are specially developed and recommended.

Additional Product Notes

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

Application References

(PubMed link indicates BioLegend citation)

1. Shirai A, et al. 1994. Cytokine 6:329. (ELISA, Neut)
2. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20. (ELISA, Neut)
3. Assenmacher M, et al. 1994. Eur. J. Immunol. 24:1097.
4. Openshaw P, et al. 1995. J. Exp. Med. 182:1357. (ICC)
5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19. (ELISA Capture)
6. Litton M, et al. 1994. J. Immunol. Methods 175:47. (IHC)
7. Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC)
8. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
9. Hara M, et al. 2001. J. Immunol. 166:3789. (Neut)
10. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
11. Lawson BR, et al. 2007. J. Immunol. 178:5366.
12. Wang W, et al. 2007. J. Immunol. 178:4885. (Neut)
13. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
14. Ohnmacht C, et al. 2008. Blood 113:2816. PubMed
15. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
16. Zavorotinskaya T, et al. 2003. Mol. Ther. 7:155. (IP)

Product Citations

1. Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed
2. Zhao M, et al. 2022. Immunity. 55:623. PubMed
3. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
4. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
5. Ogbechi J, et al. 2022. Front Immunol. 13:1001956. PubMed
6. Kenichi Shimada et al. 2018. Immunity. 49(5):873-885 . PubMed
7. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
8. Imanishi T, et al. 2020. Cell Reports. 32(3):107911. PubMed
9. Jia X, et al. 2021. Front Cell Dev Biol. 9:685522. PubMed
10. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
11. Guo P, et al. 2021. J Immunol. 207:408. PubMed
12. Kanno T, et al. 2022. Front Immunol. 13:904875. PubMed
13. Xia X, et al. 2020. J Clin Invest. 130:5180. PubMed
14. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
15. Price C, et al. 2020. Cell Host & Microbe. 27(4):571-584.e7.. PubMed
16. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
17. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed

RRID

AB_11149679 (BioLegend Cat. No. 504138)
AB_11149679 (BioLegend Cat. No. 504137)
AB_11149679 (BioLegend Cat. No. 504136)
AB_11149679 (BioLegend Cat. No. 504121)
AB_11149679 (BioLegend Cat. No. 504122)
AB_11149679 (BioLegend Cat. No. 504135)

Antigen Details

Structure

Cytokine; 15-19 kD (Mammalian)

Bioactivity

Differentiation of naïve CD4⁺ T cells to the T_H2 type, proliferation/differentiation of activated B cells, expression of class II MHC antigens, and of low affinity IgE receptors in resting B cells

Cell Sources

Mast cells, T cells, bone marrow stromal cells

Cell Targets

B cells, T cells, monocytes, endothelial cells, fibroblasts

Receptors

Heterodimer IL-4Rα (CD124); γ-subunit (CD132) in common with IL-2R, IL-7R, IL-13R, IL-15R

Cell Type

Tregs

Biology Area

Immunology

Molecular Family

Cytokines/Chemokines

Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Boulay J, et al. 1992. Curr. Opin. Immunol. 4:294.
3. Dullens H, et al. 1991. In vivo 5:567.
4. Paul W. 1991. Blood 77:1859.

Regulation

Upregulated by IL-2, platelet activating factor; downregulated by TGF-β

Gene ID

16189 View all products for this Gene ID

UniProt

View information about IL-4 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Active Protocols: Sandwich ELISA - Video
• Sandwich ELISA Protocol

Related Pages & Pathways

Related FAQs

Do you guarantee that your antibodies are totally pathogen free?

BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.

Does BioLegend test each Ultra-LEAF™ antibody by functional assay?

No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.

Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?

No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.

Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?

We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.

Other Formats

Certificate of Analysis